INCR Relative Valuation
INCR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, INCR is overvalued; if below, it's undervalued.
Historical Valuation
InterCure Ltd (INCR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -0.38. The fair price of InterCure Ltd (INCR) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 0.96 USD , InterCure Ltd is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：0.96
Fair
Undervalued
0.00
PE
1Y
3Y
5Y
0.94
EV/EBITDA
InterCure Ltd. (INCR) has a current EV/EBITDA of 0.94. The 5-year average EV/EBITDA is 0.30. The thresholds are as follows: Strongly Undervalued below -24.09, Undervalued between -24.09 and -11.90, Fairly Valued between 12.49 and -11.90, Overvalued between 12.49 and 24.68, and Strongly Overvalued above 24.68. The current Forward EV/EBITDA of 0.94 falls within the Historic Trend Line -Fairly Valued range.
1.06
EV/EBIT
InterCure Ltd. (INCR) has a current EV/EBIT of 1.06. The 5-year average EV/EBIT is -7.80. The thresholds are as follows: Strongly Undervalued below -106.32, Undervalued between -106.32 and -57.06, Fairly Valued between 41.47 and -57.06, Overvalued between 41.47 and 90.73, and Strongly Overvalued above 90.73. The current Forward EV/EBIT of 1.06 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
InterCure Ltd. (INCR) has a current PS of 0.00. The 5-year average PS is 1.42. The thresholds are as follows: Strongly Undervalued below -0.73, Undervalued between -0.73 and 0.35, Fairly Valued between 2.50 and 0.35, Overvalued between 2.50 and 3.58, and Strongly Overvalued above 3.58. The current Forward PS of 0.00 falls within the Undervalued range.
0.00
P/OCF
InterCure Ltd. (INCR) has a current P/OCF of 0.00. The 5-year average P/OCF is 5.24. The thresholds are as follows: Strongly Undervalued below -17.53, Undervalued between -17.53 and -6.14, Fairly Valued between 16.63 and -6.14, Overvalued between 16.63 and 28.02, and Strongly Overvalued above 28.02. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
InterCure Ltd. (INCR) has a current P/FCF of 0.00. The 5-year average P/FCF is 37.30. The thresholds are as follows: Strongly Undervalued below -284.75, Undervalued between -284.75 and -123.73, Fairly Valued between 198.32 and -123.73, Overvalued between 198.32 and 359.34, and Strongly Overvalued above 359.34. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
InterCure Ltd (INCR) has a current Price-to-Book (P/B) ratio of 0.43. Compared to its 3-year average P/B ratio of 0.68 , the current P/B ratio is approximately -36.31% higher. Relative to its 5-year average P/B ratio of 1.29, the current P/B ratio is about -66.50% higher. InterCure Ltd (INCR) has a Forward Free Cash Flow (FCF) yield of approximately -10.39%. Compared to its 3-year average FCF yield of -6.29%, the current FCF yield is approximately 65.06% lower. Relative to its 5-year average FCF yield of -3.62% , the current FCF yield is about 187.37% lower.
0.43
P/B
Median3y
0.68
Median5y
1.29
-10.39
FCF Yield
Median3y
-6.29
Median5y
-3.62
Competitors Valuation Multiple
The average P/S ratio for INCR's competitors is 87.83, providing a benchmark for relative valuation. InterCure Ltd Corp (INCR) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of 7.52%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of INCR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of INCR in the past 1 year is driven by Unknown.
People Also Watch
CTM
Castellum Inc
1.06USD
3.92%
ANIX
Anixa Biosciences Inc
3.42USD
4.27%
OKUR
Onkure Therapeutics Inc
2.86USD
1.42%
IPSC
Century Therapeutics Inc
1.77USD
36.15%
CATO
Cato Corp
3.22USD
6.27%
LSBK
Lake Shore Bancorp Inc
14.9USD
0.27%
GALT
Galectin Therapeutics Inc
3.2USD
-9.60%
PBHC
Pathfinder Bancorp Inc (MARYLAND)
14.2101USD
-2.00%
Frequently Asked Questions
Is InterCure Ltd (INCR) currently overvalued or undervalued?
InterCure Ltd (INCR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -0.38. The fair price of InterCure Ltd (INCR) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 0.96 USD , InterCure Ltd is Undervalued By Fair .
What is InterCure Ltd (INCR) fair value?
INCR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of InterCure Ltd (INCR) is between +Inf to +Inf according to relative valuation methord.
How does INCR's valuation metrics compare to the industry average?
The average P/S ratio for INCR's competitors is 87.83, providing a benchmark for relative valuation. InterCure Ltd Corp (INCR) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of 7.52%, this premium appears unsustainable.
What is the current P/B ratio for InterCure Ltd (INCR) as of Jan 09 2026?
As of Jan 09 2026, InterCure Ltd (INCR) has a P/B ratio of 0.43. This indicates that the market values INCR at 0.43 times its book value.
What is the current FCF Yield for InterCure Ltd (INCR) as of Jan 09 2026?
As of Jan 09 2026, InterCure Ltd (INCR) has a FCF Yield of -10.39%. This means that for every dollar of InterCure Ltd’s market capitalization, the company generates -10.39 cents in free cash flow.
What is the current Forward P/E ratio for InterCure Ltd (INCR) as of Jan 09 2026?
As of Jan 09 2026, InterCure Ltd (INCR) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of InterCure Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for InterCure Ltd (INCR) as of Jan 09 2026?
As of Jan 09 2026, InterCure Ltd (INCR) has a Forward P/S ratio of 0.00. This means the market is valuing INCR at $0.00 for every dollar of expected revenue over the next 12 months.